Endoplasmic reticulum aminopeptidase 2, ERAP2, is an emerging pharmacological target in cancer immunotherapy and control of autoinflammatory diseases, as it involved antigen processing. It has been linked to the risk development spondyloarthritis, associates with immune infiltration tumours strongly predicts overall survival for patients receiving check-point inhibitor therapy. While some selec...